MIAMI, FL--At the close of yesterday's market, Novus (OTC Pink: NDEV) CEO, Frank Labrozzi states, "Market reaction relating to our business model was extremely positive, along with numerous inquires relating new business development."
In addition, Novus' management unveiled its business model called "Enterprise Solutions." This is where we provide a support structure to companies from everything from seed to sale (without handling the MMJ plant itself). This includes direct consultation for grower to retailer; the platform will be turnkey in acquisition of real property, select and install the best equipment according to current state laws, security and point of purchase equipment/software and possible financing. Revenue is realized by delivering aforementioned to the MMJ licensor with lease back provision to Novus MMJ, Inc. using and building our Brand Name (similar to how a ran franchisor will set up a facility for a franchisee). This business model positions Novus MMJ, Inc. profit margins at 25%-35%, EBITDA, with limited overhead.
The reason for this approach is the lack of barrier of entry in the MMJ industry. Green-Rx-Pharm can educate and help less business savvy entrepreneurs and hone in on their business skills with proper guidance, which is experienced in a less mature industry sector. Learn more;www.ndev.biz
Our focus in the ancillary business products and services in a vertical integration approach;
-Tactical Grow House Design
-POS For Retail Sales
-Food Product Development
Novus is comprised of seasoned Wall Street veterans that have focused its business model in the cannabis industry. Management and its proposed future Board of Directors areas of expertise will diversify in Healthcare, Physicians Education, Pharma R&D, Compliance and Business Development. NDEV will work as an outside developer and since it not Federally approved it will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.
For investor Relations contact:
Bridgewater Communications Group
Main Tel: (855) 4-BCG-INFO / (855) 422-4463
Gary F. Labrozzi
SOURCE: Novus Acquisition & Development Corp